HOME NEWS EARNINGS RESULTS PICKS STRATEGY BLOG CONTACT SUBSCRIBE LOGIN SUBSCRIBE JOIN FREE
LOADING
Price Investing Group
← Back to Research Watchlist
TVTX
Travere Therapeutics Inc
Healthcare Biotechnology · California, USA · Reports in usd
Market Cap: $5.28B
Market Cap
$5.28B
Enterprise Val
$5.35B
P/E Ratio
-246.64
P/B Ratio
53.52
Trailing PEG (1Y)
16.56
As Of
Jul 29, 2026

Overview & Key Metrics

Reporting period: Mar 31, 2026 · Q1 2026
Book Value$98.7M
Gross Margin98.47%
Profit Margin98.47%
Return on Equity-26.79%
Return on Assets-3.80%
Current Ratio3.13
Debt/Equity3.32
LT Debt/Equity3.26
Revenue Per Share1.38

Income Statement

Mar 31, 2026
Revenue$127.2M
Cost of Revenue$2.0M
Gross Profit$125.2M
R&D$57.1M
SG&A$80.3M
Operating Expenses$162.2M
Operating Income-$36.9M
Interest Expense$2.3M
Tax Expense-$120.0K
Net Income-$37.1M
EPS (Basic)$-0.40
EPS (Diluted)$-0.40
EBIT-$34.9M
EBITDA-$9.7M
Consolidated Income-$37.1M
Non-Controlling Interests$0.00

Balance Sheet

Mar 31, 2026
Cash & Equivalents$78.4M
Accounts Receivable$87.3M
Inventory$37.1M
Current Assets$392.7M
LT Investments$0.00
Property, Plant & Equipment$13.3M
Intangibles$110.0M
Non-Current Assets$162.5M
Total Assets$555.2M
Accounts Payable$12.9M
Current Debt$6.0M
Current Liabilities$125.4M
LT Debt$321.6M
Non-Current Liabilities$331.0M
Total Liabilities$456.5M
Total Debt$327.7M
Retained Earnings-$1.51B
Shareholder Equity$98.7M
Shares Outstanding92,241,550

Cash Flow Statement

Mar 31, 2026
Operating Cash Flow-$40.4M
Investing Cash Flow$21.5M
Financing Cash Flow$4.2M
CapEx-$22.2M
Free Cash Flow-$62.5M
Depreciation & Amort.$25.2M
Stock-Based Comp$16.1M
Acquisitions / Disposals$0.00
Investment Activity$43.7M
Debt Issued/Repaid$0.00
Equity Issued/Repaid$4.7M
Dividends Paid$0.00
Net Change in Cash-$14.7M
Data cached · Meta cache · Daily cache · Statements cache · TTL 24h